Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action

被引:29
作者
Ionut, Viorica [1 ]
Liberty, Idit F. [1 ]
Hucking, Katrin [1 ]
Lottati, Maya [1 ]
Stefanovski, Darko [1 ]
Zheng, Dan [1 ]
Bergman, Richard N. [1 ]
机构
[1] Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, Los Angeles, CA 90033 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM | 2006年 / 291卷 / 04期
关键词
glucagon-like peptide-1; insulin secretion; portal; meal test; neural mechanism;
D O I
10.1152/ajpendo.00106.2005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The insulinotropic intestinal hormone GLP-1 is thought to exert one of its effects by direct action on the pancreatic beta-cell receptors. GLP-1 is rapidly degraded in plasma, such that only a small amount of the active form reaches the pancreas, making it questionable whether this amount is sufficient to produce a direct incretin effect. The aim of our study was to assess, in a dog model, the putative incretin action of GLP-1 acting directly on the beta-cell in the context of postprandial rises in GLP-1 and glucose. Conscious dogs were fed a high-fat, high-carbohydrate meal, and insulin response was measured. We also infused systemic glucose plus GLP-1, or glucose alone, to simulate the meal test values of these variables and measured insulin response. The results were as follows: during the meal, we measured a robust insulin response (52 +/- 9 to 136 +/- 14 pmol/l, P < 0.05 vs. basal) with increases in portal glucose and GLP-1 but only limited increases in systemic glucose (5.3 +/- 0.1 to 5.7 +/- 0.1 mmol/l, P = 0.1 vs. basal) and GLP-1 (6 +/- 0 to 9 +/- 1 pmol/l, P = 0.5 vs. basal). Exogenous infusion of systemic glucose and GLP-1 produced a moderate increase in insulin (43 +/- 5 to 84 +/- 15 pmol/l, 43% of the meal insulin). However, infusion of glucose alone, without GLP- 1, produced a similar insulin response (37 +/- 6 to 82 +/- 14 pmol, 53% of the meal insulin, P = 0.7 vs. glucose and GLP-1 infusion). In conclusion, in dogs with postprandial rises in systemic glucose and GLP- 1, the hormone might not have a direct insulinotropic effect and could regulate glycemia via indirect, portohepatic-initiated neural mechanisms.
引用
收藏
页码:E779 / E785
页数:7
相关论文
共 37 条
[1]   Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice [J].
Ahrén, B .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2004, 286 (02) :R269-R272
[2]   Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms [J].
Balkan, B ;
Li, X .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2000, 279 (04) :R1449-R1454
[3]   SHAM FEEDING-INDUCED CEPHALIC PHASE INSULIN RELEASE IN THE RAT [J].
BERTHOUD, HR ;
JEANRENAUD, B .
AMERICAN JOURNAL OF PHYSIOLOGY, 1982, 242 (04) :E280-E285
[4]   Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor [J].
Burcelin, R ;
Da Costa, A ;
Drucker, D ;
Thorens, B .
DIABETES, 2001, 50 (08) :1720-1728
[5]   ENTERAL ENHANCEMENT OF GLUCOSE DISPOSITION BY BOTH INSULIN-DEPENDENT AND INSULIN-INDEPENDENT PROCESSES - A PHYSIOLOGICAL-ROLE OF GLUCAGON-LIKE PEPTIDE-I [J].
DALESSIO, DA ;
PRIGEON, RL ;
ENSINCK, JW .
DIABETES, 1995, 44 (12) :1433-1437
[6]   Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region [J].
Dardevet, D ;
Moore, MC ;
Neal, D ;
DiCostanzo, CA ;
Snead, W ;
Cherrington, AD .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2004, 287 (01) :E75-E81
[7]   Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs [J].
Deacon, CF ;
Wamberg, S ;
Bie, P ;
Hughes, TE ;
Holst, JJ .
JOURNAL OF ENDOCRINOLOGY, 2002, 172 (02) :355-362
[8]   BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS [J].
DEACON, CF ;
NAUCK, MA ;
TOFTNIELSEN, M ;
PRIDAL, L ;
WILLMS, B ;
HOLST, JJ .
DIABETES, 1995, 44 (09) :1126-1131
[9]   Biological actions and therapeutic potential of the glucagon-like peptides [J].
Drucker, DJ .
GASTROENTEROLOGY, 2002, 122 (02) :531-544
[10]   Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans - Studies with the antagonist exendin 9-39 [J].
Edwards, CMB ;
Todd, JF ;
Mahmoudi, M ;
Wang, ZL ;
Wang, RM ;
Ghatei, MA ;
Bloom, SR .
DIABETES, 1999, 48 (01) :86-93